[go: up one dir, main page]

PE20220578A1 - Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades - Google Patents

Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades

Info

Publication number
PE20220578A1
PE20220578A1 PE2021002219A PE2021002219A PE20220578A1 PE 20220578 A1 PE20220578 A1 PE 20220578A1 PE 2021002219 A PE2021002219 A PE 2021002219A PE 2021002219 A PE2021002219 A PE 2021002219A PE 20220578 A1 PE20220578 A1 PE 20220578A1
Authority
PE
Peru
Prior art keywords
alkyl
cycloalkyl
imidazo
diseases
treatment
Prior art date
Application number
PE2021002219A
Other languages
English (en)
Inventor
Emily Anne Peterson
Ryan Evans
Fang Gao
Philippe Bolduc
Magnus Pfaffenbach
Zhili Xin
Tricia May-Dracka
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of PE20220578A1 publication Critical patent/PE20220578A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La presente invencion esta referida a compuestos derivados de imidazo[1,2-a]piridinilo de formula (I), en donde R1 se selecciona de halo, alquilo C1-5, cicloalquilo C3-6, -alquilo C1-2-cicloalquilo C3-6, un heterociclo de 4 a 7 miembros que contiene 1 a 2 heteroatomos seleccionados de forma independiente de N, S y O entre otros; R2 es hidrogeno, alquilo C1-4 o halogeno; R3 se selecciona de un heteroarilo de 5 o 6 miembros con 1 a 3 heteroatomos seleccionados de N, O y S, fenilo, un heterociclo de 5-6 miembros parcial o completamente saturado con 1 a 2 heteroatomos, un cicloalquilo C3-6 parcial o completamente saturado, entre otros; X1 y X2 se seleccionan de N, CH y CR5, en donde solamente uno de X1 o X2 puede ser N. Dichos compuestos inhiben la actividad de IRAK4 (cinasas asociadas al receptor de interleucina 4 ). Tambien refiere a una composicion farmaceutica que los comprende, siendo utiles en el en el tratamiento y el control de enfermedades o trastornos que incluyen una enfermedad inflamatoria, una enfermedad autoinmunitaria, cancer, una enfermedad cardiovascular, entre otros.
PE2021002219A 2019-06-27 2020-06-24 Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades PE20220578A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962867589P 2019-06-27 2019-06-27
PCT/US2020/039359 WO2020263980A1 (en) 2019-06-27 2020-06-24 Imidazo[1,2-a]pyridinyl derivatives and their use in the treatment of disease

Publications (1)

Publication Number Publication Date
PE20220578A1 true PE20220578A1 (es) 2022-04-20

Family

ID=71528117

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021002219A PE20220578A1 (es) 2019-06-27 2020-06-24 Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades

Country Status (21)

Country Link
US (1) US20230087118A1 (es)
EP (1) EP3990454A1 (es)
JP (1) JP7576581B2 (es)
KR (1) KR20220027196A (es)
CN (1) CN114245796B (es)
AR (1) AR119234A1 (es)
AU (1) AU2020301230A1 (es)
BR (1) BR112021026350A2 (es)
CA (1) CA3145040A1 (es)
CL (1) CL2021003452A1 (es)
CO (1) CO2022000659A2 (es)
CR (1) CR20220037A (es)
IL (1) IL289164A (es)
JO (1) JOP20210322A1 (es)
MA (1) MA56390A (es)
MX (1) MX2021015498A (es)
PE (1) PE20220578A1 (es)
PH (1) PH12021553223A1 (es)
TW (1) TW202115075A (es)
UY (1) UY38766A (es)
WO (1) WO2020263980A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7576552B2 (ja) * 2019-01-18 2024-10-31 バイオジェン・エムエイ・インコーポレイテッド イミダゾ［１，２－ａ］ピリジニル誘導体及び疾患の処置におけるその使用
US11866405B2 (en) 2020-12-10 2024-01-09 Astrazeneca Ab Substituted indazoles as IRAK4 inhibitors
KR20230134500A (ko) * 2020-12-22 2023-09-21 바이오젠 엠에이 인코포레이티드 Irak4 억제제로서의 이미다조[1,2-a]피리딘 유도체및 질환의 치료에서의 그의 용도
JP2024501281A (ja) * 2020-12-22 2024-01-11 バイオジェン・エムエイ・インコーポレイテッド Ｉｒａｋ４阻害剤としての２ｈ－インダゾール誘導体及び疾患の治療におけるそれらの使用
EP4361151A4 (en) * 2021-06-21 2025-06-11 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company Tricyclic compound as a GPR84 antagonist
WO2023283610A1 (en) * 2021-07-07 2023-01-12 Biogen Ma Inc. Compounds for targeting degradation of irak4 proteins
KR20240051921A (ko) 2022-02-14 2024-04-22 아스트라제네카 아베 Irak4 억제제
LT4387730T (lt) * 2022-09-08 2025-09-10 Redx Pharma Limited Uolienų inhibitoriaus kietosios formos
EP4389747A1 (en) * 2022-12-21 2024-06-26 Dark Blue Therapeutics Ltd Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors
EP4638447A1 (en) * 2022-12-21 2025-10-29 Dark Blue Therapeutics Ltd Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors
AU2024262043A1 (en) * 2023-04-24 2025-11-20 Shanghai SIMR Biotechnology Co., Ltd Imidazopyridine or imidazopyrazine compound, preparation method therefor, and pharmaceutical composition and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070732A1 (en) * 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2012007375A1 (en) * 2010-07-13 2012-01-19 F. Hoffmann-La Roche Ag Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators
WO2016031815A1 (ja) * 2014-08-26 2016-03-03 武田薬品工業株式会社 複素環化合物
US10059708B2 (en) * 2016-04-26 2018-08-28 Northwestern University Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
WO2018234343A1 (en) * 2017-06-21 2018-12-27 F. Hoffmann-La Roche Ag BENZOFURANES AS MODULATORS OF IRAQ4

Also Published As

Publication number Publication date
MX2021015498A (es) 2022-04-20
WO2020263980A8 (en) 2021-03-04
JP7576581B2 (ja) 2024-10-31
CN114245796A (zh) 2022-03-25
TW202115075A (zh) 2021-04-16
PH12021553223A1 (en) 2022-10-17
WO2020263980A1 (en) 2020-12-30
KR20220027196A (ko) 2022-03-07
MA56390A (fr) 2022-05-04
CA3145040A1 (en) 2020-12-30
AR119234A1 (es) 2021-12-01
UY38766A (es) 2021-01-29
US20230087118A1 (en) 2023-03-23
IL289164A (en) 2022-02-01
JP2022539373A (ja) 2022-09-08
CN114245796B (zh) 2024-07-30
JOP20210322A1 (ar) 2023-01-30
BR112021026350A2 (pt) 2022-05-10
AU2020301230A1 (en) 2022-01-06
CL2021003452A1 (es) 2022-08-19
EP3990454A1 (en) 2022-05-04
CO2022000659A2 (es) 2022-04-29
CR20220037A (es) 2022-06-03

Similar Documents

Publication Publication Date Title
PE20220578A1 (es) Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades
PE20170003A1 (es) Compuestos heterociclicos y usos de los mismos
PE20210406A1 (es) Inhibidores de inflamasoma nlrp3
CO2022001357A2 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PE20160540A1 (es) Inhibidores de bromodominios
PE20230322A1 (es) Aminotiazoles sustituidos como inhibidores de dgkzeta para la activacion inmune
PE20190732A1 (es) Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
PE20210658A1 (es) Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat)
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20080527A1 (es) Derivado de pirimidina como inhibidor de la fosfatidilinositol 3-quinasa (pi3k)
PE20090370A1 (es) Derivados de heterociclo fusionado como inhibidores de quinasa
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
AR017852A1 (es) COMPUESTOS DE PIRAZOLO (3,4-b)PIRIDINA Y SUS SALES, UTILES COMO INHIBIDORES DE LAS PROTEINA-QUINASAS DEPENDIENTES DE CICLINA, Y LAS COMPOSICIONESFARMACEUTICAS QUE LOS CONTIENEN, EVENTUALMENTE ASOCIADOS CON UN AGENTE ANTICANCER.
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
PE20120534A1 (es) PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt
NI201000011A (es) Derivados de pirimidina 934.
NO20061978L (no) Imidazopyridinsubstituerte tropanderivater med CCR5-reseptorantagonist aktivitet for behandling av HIV og inflammasjon
PE20200932A1 (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
PE20110560A1 (es) NUEVOS DERIVADOS DE TRIAZOLO[4,3-a]PIRIDINA, SU PROCEDIMIENTO DE PREPARACION, SU APLICACION COMO MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS Y NUEVA UTILIZACION PARTICULARMENTE COMO INHIBIDORES DE MET
AR073262A1 (es) Derivados de pirazolo[5, 1-b]oxazol, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por antagonistas de crf1.
PE20091083A1 (es) Moduladores tieno- y furo- pirimidina del receptor de histamina h4
PE20211377A1 (es) Derivados de triazolquinoxalina adicionalmente sustituidos